Zobrazeno 1 - 10
of 534
pro vyhledávání: '"DEPLETION THERAPY"'
Autor:
Jia Wang, Haotao Zheng, Jia Wei, Jiaping Wu, Ziyang Feng, Xueqin Chen, Yangsicheng Liu, Wenxin Qin, Xiude Qin, Fanxin Kong
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of
Externí odkaz:
https://doaj.org/article/c2bed5ff8abd4d97bdfcf6c58e9aa07b
Autor:
William H. Robinson, David Fiorentino, Lorinda Chung, Larry W. Moreland, Malavika Deodhar, Mary Beth Harler, Carrie Saulsbery, Rebecca Kunder
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
B-cell depletion therapy (BCDT) has been employed to treat autoimmune disease for ~20 years. Immunoglobulin G1 (IgG1) monoclonal antibodies targeting CD20 and utilizing effector function (eg, antibody-dependent cellular cytotoxicity, complement-depen
Externí odkaz:
https://doaj.org/article/f6ca48ff0e614052bb2506a211f875af
Autor:
Dmytro Ivanov, Lutz T. Weber, Elena Levtchenko, Liudmyla Vakulenko, Mariia Ivanova, Iryna Zavalna, Yelizaveta Lagodych, Ninel Boiko
Publikováno v:
Biomedicines, Vol 12, Iss 11, p 2600 (2024)
Background: Steroid-sensitive nephrotic syndrome (SSNS) and steroid-resistant nephrotic syndrome (SRNS) significantly affect children’s quality of life. There are frequent relapses in SSNS and progression in SRNS. IPNA guidelines suggest that monoc
Externí odkaz:
https://doaj.org/article/d1b9c272fff24fb09d4beb9de1238a1f
Publikováno v:
Kidney Medicine, Vol 6, Iss 4, Pp 100791- (2024)
Resistance to rituximab B-cell depletion therapy is a clinically pertinent adverse sequela that can have significant implications for the treatment of immune-mediated glomerular diseases. The true incidence of rituximab resistance remains unknown; ho
Externí odkaz:
https://doaj.org/article/c05d739cc38444a795f59e1f36917219
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
ObjectiveTo assess the effect of B cell depletion therapy (BCDT) on circulating T follicular helper (cTfh) and circulating T helper 17 (cTh17) cells and its relation to clinical improvement in patients with myasthenia gravis (MG).Methods28 anti-AchR
Externí odkaz:
https://doaj.org/article/74b3c04d5eef4771b608663ad58fdf47
Autor:
Yuriko Sueda, Hirokazu Tokuyasu, Momoka Atsuta, Hiromitsu Sakai, Katsunori Arai, Chika Esumi, Misato Mochizuki, Tomoki Itohara, Naoki Fujisawa, Akira Yamasaki
Publikováno v:
Respiratory Medicine Case Reports, Vol 52, Iss , Pp 102131- (2024)
A 68-year-old woman with follicular lymphoma was treated with chemotherapy, including the anti-CD20 monoclonal antibody obinutuzumab, and achieved remission. A month after the administration of obinutuzumab, the patient contracted coronavirus disease
Externí odkaz:
https://doaj.org/article/4422745a2baf40869611f2b9c9b9da84
Autor:
Miriam L. Fichtner, Kenneth B. Hoehn, Easton E. Ford, Marina Mane-Damas, Sangwook Oh, Patrick Waters, Aimee S. Payne, Melissa L. Smith, Corey T. Watson, Mario Losen, Pilar Martinez-Martinez, Richard J. Nowak, Steven H. Kleinstein, Kevin C. O’Connor
Publikováno v:
Acta Neuropathologica Communications, Vol 10, Iss 1, Pp 1-16 (2022)
Abstract Myasthenia gravis (MG) is an autoantibody-mediated autoimmune disorder of the neuromuscular junction. A small subset of patients (
Externí odkaz:
https://doaj.org/article/8b2f0e5081c74f97a58e8de4171c3ffb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yibo Zhan, Min Zhao, Xiaojun Li, Huiying Ouyang, Chenghao Du, Guixian Chen, Zhenzhen Lou, Haoxuan Chen, Yuanqi Zhao, Haoyou Xu
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
ObjectiveTo report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab.Case presentationA 42-
Externí odkaz:
https://doaj.org/article/6684857855d045258cff1e3fcfafdb15